Clinical trials: Psilocybin
Depressive Disorder, Major
A Study of Psilocybin for Major Depressive Disorder (MDD)
One hundred participants, ages 21 to 65, who meet Diagnostic and Statistical Manual of Mental Disorders (DSM-5) criteria for major depressive disorder (MDD) will be stratified by study site and randomized with a 1-to-1 allocation…
- Trial name
- NCT03866174
- Testing
- Psilocybin, Niacin, Set and Setting (SaS) Protocol
- Where
- 11 sites in United States
- Volunteers
- 347 people
- Sponsor
- Usona Institute
Hematopoietic and Lymphatic System Neoplasm, Metastatic Malignant Solid Neoplasm
Psilocybin-Assisted Therapy for the Treatment of Cancer-Related Anxiety in Patients With Metastatic Cancer
This phase I/II trial tests the safety and side effects of psilocybin in combination with therapy for the treatment of patients with metastatic cancer and symptoms of anxiety and/or depression.
- Trial name
- NCT05847686
- Testing
- Counseling, Psilocybin, Questionnaire Administration
- Where
- United States
- Volunteers
- 55 people
- Sponsor
- University of Washington
Major Depressive Disorder
Effects of Psilocybin in Major Depressive Disorder
The proposed pilot study will assess whether people with major depressive disorder experience psychological and behavioral benefits and/or harms from psilocybin.
- Trial name
- NCT03181529
- Testing
- Psilocybin
- Where
- United States
- Volunteers
- 27 people
- Sponsor
- Johns Hopkins University
Burnout, Caregiver, Burnout, Professional
Frontline Clinician Psilocybin Study
This study aims to investigate the effects of a single dose of psilocybin, delivered in the contextof pre- and post-dose psychotherapy, on symptoms of depression and burnout suffered by healthcare clinicians as a result of…
- Conditions
- Burnout, Caregiver, Burnout, Professional, COVID-19, Depression
- Trial name
- NCT05163496
- Testing
- Psilocybin (Usona Institute)
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- University of Washington
Depressive Disorder, Major
Psilocybin vs Escitalopram for Major Depressive Disorder: Comparative Mechanisms
This is a randomised double-blind clinical trial. The aim is to compare the efficacy and mechanisms of action of psilocybin, the primary psychoactive substance in 'magic mushrooms', with the selective serotonin reuptake inhibitor…
- Trial name
- Psilodep-RCT (NCT03429075)
- Testing
- Psilocybin + Escitalopram
- Where
- United Kingdom
- Volunteers
- 59 people
- Sponsor
- Imperial College London
Parkinson Disease, Depression
Psilocybin Therapy for Depression and Anxiety in Parkinson's Disease
The purpose of this study is to determine the safety, tolerability, and feasibility of psilocybin therapy for depression and anxiety in people with Parkinson's disease.
- Conditions
- Parkinson Disease, Depression, Anxiety
- Trial name
- PDP1 (NCT04932434)
- Testing
- Psilocybin therapy
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Joshua Woolley, MD, PhD
Nicotine Dependence
Psilocybin-facilitated Smoking Cessation Treatment: A Pilot Study
One of the most promising lines of investigation for the therapeutic use of hallucinogens in the 1960s and 1970s was in the treatment of drug dependence.
- Trial name
- NCT01943994
- Testing
- Psilocybin-assisted treatment, Nicotine Replacement Therapy (NRT)
- Where
- 2 sites in United States
- Volunteers
- 82 people, healthy volunteers welcome
- Sponsor
- Johns Hopkins University
Fibromyalgia
Open-label Study to Assess the Safety and Efficacy of Psilocybin With Psychotherapy in Adult Participants With Fibromyalgia
The pressing need for effective fibromyalgia (FM) treatments, the known safety of psilocybin therapy, and the mechanistic plausibility for potential benefit provide a backdrop for investigating psilocybin therapy as a treatment…
- Trial name
- NCT05128162
- Testing
- Psilocybin, Psychotherapy
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- Kevin Boehnke
Hospice, Psilocybin
Pilot Study of Psilocybin-Assisted Therapy for Demoralization in Patients Receiving Hospice Care
The overall objective of this study is to develop and pilot test a novel regimen of psilocybin-assisted psychotherapy for demoralization in patients receiving hospice care.
- Conditions
- Hospice, Psilocybin, Demoralization, Terminal Illness
- Trial name
- PATH (NCT04950608)
- Testing
- Psilocybin, Psychotherapy
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Yvan Beaussant, MD, MSci
Perception Disturbance, Visual Suppression
Visual Surround Suppression and Perceptual Expectation Under Psilocybin
The prospective pilot study will address the critical need for more precise characterizations of the acute visual effects of the drug psilocybin by measuring the impact of acute psilocybin intoxication on a perceptual task known…
- Conditions
- Perception Disturbance, Visual Suppression, Psychedelic Experiences
- Trial name
- NCT04424225
- Testing
- Psilocybin, Niacin
- Where
- United States
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- University of Minnesota
Cocaine-Related Disorders
Psilocybin-facilitated Treatment for Cocaine Use
The primary purpose of this study is to evaluate the feasibility and estimate the efficacy of psilocybin-facilitated treatment for cocaine use.
- Trial name
- NCT02037126
- Testing
- Psilocybin, Diphenhydramine
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- University of Alabama at Birmingham
Distress, Depression
Psilocybin-assisted Group Therapy for Demoralization in Long-term AIDS Survivors
The purpose of this study is to determine whether psilocybin-assisted group psychotherapy is a safe and feasible treatment for demoralization in long-term AIDS survivors (LTAS).
- Conditions
- Distress, Depression, Grief
- Trial name
- NCT02950467
- Testing
- Psilocybin, Modified brief Supportive Expressive Group Therapy
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Joshua Woolley
Treatment Resistant Depression
The Safety and Efficacy Of Psilocybin as an Adjunctive Therapy in Participants With Treatment Resistant Depression
The Safety and Efficacy of Psilocybin as an Adjunctive Therapy in Participants with Treatment-Resistant Depression
- Trial name
- NCT04739865
- Testing
- Psilocybin
- Where
- 2 sites in United States, Ireland
- Volunteers
- 19 people
- Sponsor
- COMPASS Pathways
Alcohol Dependence
Effects and Therapeutic Potential of Psilocybin in Alcohol Dependence
This trial is an open-label pilot study (N = 10) designed to assess the effects of psilocybin in alcohol dependent participants, demonstrate the feasibility of the integrated behavioral/pharmacologic intervention, and provide…
- Trial name
- NCT01534494
- Testing
- Psilocybin
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- University of New Mexico
Depressive Symptoms, Anxiety
Psychopharmacology of Psilocybin in Cancer Patients
This research is being done to study the psychological effects of psilocybin in cancer patients. Psilocybin is a naturally occurring substance found in some mushrooms that some cultures have used for centuries in religious…
- Conditions
- Depressive Symptoms, Anxiety, Cancer
- Trial name
- NCT00465595
- Testing
- psilocybin
- Where
- United States
- Volunteers
- 56 people
- Sponsor
- Johns Hopkins University
Treatment Resistant Depression
The Safety and Efficacy of Psilocybin in Participants With Treatment Resistant Depression
The Safety and Efficacy of Psilocybin in Participants with Treatment Resistant Depression
- Trial name
- P-TRD (NCT03775200)
- Testing
- Psilocybin
- Where
- 25 sites in United States, Canada and 8 more
- Volunteers
- 233 people
- Sponsor
- COMPASS Pathways
Healthy
Persisting Effects of Psilocybin
The proposed pilot study will assess whether ingestion of a classic hallucinogen (psilocybin) leads to changes in emotion processing and neural circuitry that may predict repeated self-administration of this drug and underlie an…
- Trial name
- NCT02971605
- Testing
- Psilocybin
- Where
- United States
- Volunteers
- 13 people, healthy volunteers welcome
- Sponsor
- Johns Hopkins University
Body Dysmorphic Disorders
Safety and Efficacy of Psilocybin for Body Dysmorphic Disorder
In this pilot study 12 adult outpatients with body dysmorphic disorder that has not responded to at least one adequate trial of a serotonin reuptake inhibitor will be treated openly with a single oral dose of psilocybin.
- Trial name
- NCT04656301
- Testing
- Psilocybin
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- New York State Psychiatric Institute
Obsessive-Compulsive Disorder
Efficacy of Psilocybin in OCD: a Double-Blind, Placebo-Controlled Study.
This study aims to investigate the effects of oral psilocybin on OCD symptomatology and provide the first evidence of the neural mechanism that may mediate psilocybin's purported therapeutic effects on OCD.
- Trial name
- NCT03356483
- Testing
- Psilocybin (0.25mg/kg), Niacin (250mg)
- Where
- United States
- Volunteers
- 28 people
- Sponsor
- Yale University
Alcohol Dependence
A Double-Blind Trial of Psilocybin-Assisted Treatment of Alcohol Dependence
Several lines of evidence suggest that classic hallucinogens such as psilocybin can facilitate behavior change in addictions such as alcohol dependence.
- Trial name
- NCT02061293
- Testing
- Psilocybin, Diphenhydramine, Motivational Enhancement and Taking Action (META)
- Where
- 2 sites in United States
- Volunteers
- 95 people
- Sponsor
- NYU Langone Health